Does TISLELIZUMAB Cause Reactive capillary endothelial proliferation? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Reactive capillary endothelial proliferation have been filed in association with TISLELIZUMAB (TEVIMBRA). This represents 0.1% of all adverse event reports for TISLELIZUMAB.
5
Reports of Reactive capillary endothelial proliferation with TISLELIZUMAB
0.1%
of all TISLELIZUMAB reports
1
Deaths
0
Hospitalizations
How Dangerous Is Reactive capillary endothelial proliferation From TISLELIZUMAB?
Of the 5 reports, 1 (20.0%) resulted in death.
Is Reactive capillary endothelial proliferation Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TISLELIZUMAB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does TISLELIZUMAB Cause?
Myelosuppression (2,142)
White blood cell count decreased (327)
Neutrophil count decreased (277)
Hepatic function abnormal (221)
Pruritus (213)
Rash (208)
Platelet count decreased (183)
Pyrexia (175)
Nausea (165)
Diarrhoea (145)
What Other Drugs Cause Reactive capillary endothelial proliferation?
CAMRELIZUMAB (41)
CAPECITABINE (19)
CISPLATIN (19)
DOCETAXEL\DOCETAXEL ANHYDROUS (17)
OXALIPLATIN (11)
ATEZOLIZUMAB (10)
BEVACIZUMAB (10)
PEMBROLIZUMAB (7)
SINTILIMAB (7)
TORIPALIMAB (6)
Which TISLELIZUMAB Alternatives Have Lower Reactive capillary endothelial proliferation Risk?
TISLELIZUMAB vs TISOTUMAB VEDOTIN
TISLELIZUMAB vs TISOTUMAB VEDOTIN-TFTV
TISLELIZUMAB vs TITANIUM DIOXIDE\ZINC
TISLELIZUMAB vs TIVICAY
TISLELIZUMAB vs TIVOZANIB